One critical and lasting consequence of the pandemic will be the accelerated adoption of digital technology in health care delivery. We conclude by discussing ways in which the changes wrought by COVID-19 from a health care, policy, and economics perspective can add value and are likely to endure postpandemic (Diabetes Technology and Therapeutics)
Diabetes News
Tag: COVID-19
Metformin Use Is Associated With Reduced Mortality in a Diverse Population With COVID-19 and Diabetes
These results suggest that while diabetes is an independent risk factor for COVID-19-related mortality, this risk is dramatically reduced in subjects taking metformin prior to diagnosis of COVID-19, raising the possibility that metformin may provide a protective approach in this high risk population (Frontiers in Endocrinology)
Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland
Overall risks of fatal or critical care unit-treated COVID-19 were substantially elevated in those with type 1 and type 2 diabetes compared with the background population. The risk of fatal or critical care unit-treated COVID-19, and therefore the need for special protective measures, varies widely among those with diabetes but can be predicted reasonably well using previous clinical history (The Lancet Diabetes & Endocrinology)
Effect of remote management on comprehensive management of diabetes mellitus during the COVID-19 epidemic
During the COVID-19 epidemic, diabetes treatment has been facing new challenges, and the traditional treatment mode is limited. Remote management can increase TIR without increasing the risk of hypoglycemia. Remote management can prevent weight gain and improve patients’ self-management and compliance during the COVID-19 epidemic (Primary Care Diabetes)
Widespread sensory neuropathy in diabetic patients hospitalized with severe COVID-19 infection
Severe COVID-19 infection with hypoxemia is associated with neuropathic symptoms and widespread sensory dysfunction in patients with DM (Diabetes Research and Clinical Practice)
Endocrinology in the time of COVID-19: Diagnosis and management of gestational diabetes mellitus
We suggest pragmatic options for screening of GDM in a pandemic setting based on blood tests, and risk calculators applied to underlying risk factors (European Journal of Endocrinology)
Caring for Hospitalized Patients with Diabetes Mellitus, Hyperglycemia, and COVID-19: Bridging the Remaining Knowledge Gaps
Changes in diabetes-related protocols and new technology can be deployed in the inpatient setting to potentially improve healthcare worker and patient safety; however, one must weigh the risks and benefits of implementation during a pandemic (Current Diabetes Reports)
Glycemic control before admission is an important determinant of prognosis in patients with coronavirus disease 2019
HbA1c was an independent risk factor for poor outcomes in coronavirus disease 2019 patients. Severe pulmonary infection and consequent acute respiratory distress syndrome might be the primary causes of death in insufficient glycemic control patients (Journal of Diabetes Investigation)
A Collaborative OverView and Insight into Diabetes Services before and after the COVID-19 pandemic
This report is part of an initiative led by Lesley Mills (Nurse Consultant); the group included Diabetes Specialist Nurses and Practitioners, Consultants (ABCD, Diabetes UK)
Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19
In this multicenter, case-control, retrospective, observational study of patients with type 2 diabetes admitted to the hospital for COVID-19, sitagliptin treatment at the time of hospitalization was associated with reduced mortality and improved clinical outcomes as compared with standard-of-care treatment (Diabetes Care)
Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study
The results of this nationwide analysis in England show that type 1 and type 2 diabetes were both independently associated with a significant increased odds of in-hospital death with COVID-19 (The Lancet Diabetes & Endocrinology)
Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study
Deaths in people with type 1 and type 2 diabetes rose sharply during the initial COVID-19 pandemic in England. Increased COVID-19-related mortality was associated not only with cardiovascular and renal complications of diabetes but, independently, also with glycaemic control and BMI (The Lancet Diabetes & Endocrinology)
Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study
The results of this nationwide analysis in England show that type 1 and type 2 diabetes were both independently associated with a significant increased odds of in-hospital death with COVID-19 (The Lancet Diabetes & Endocrinology)
Coronavirus infection (SARS-CoV-2) in obesity and diabetes comorbidities: is heat shock response determinant for the disease complications?
A new hypothesis that aims to explain the increased severity of SARS-CoV-2 infection in people with metabolic diseases, and the possible benefits of HSR-inducing therapies to improve the inflammatory profile in these patients (Diabetology & Metabolic Syndrome)
ABCD COVID-19 & Diabetes: UK national audit
This audit aims to explore the clinical features and presentation of people admitted with diabetes and COVID-19. Through capturing detailed real-world data on the clinical presentation, co-morbidities, therapies and outcomes we hope to gain better insight into the impact of COVID-19 on those living with diabetes (ABCD)
Fasting blood glucose at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes
FBG ≥7.0 mmol/l at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes (Diabetologia)
Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose-Lowering Medication
C-reactive protein may help to identify patients with diabetes who are at greater risk of dying during hospitalization. Older patients with diabetes were prone to death related to COVID-19. Attention needs to be paid to patients with diabetes and COVID-19 who use insulin. ACEI/ARB use showed no significant impact on patients with diabetes and hypertension who have COVID-19 (Diabetes Care)
Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19
We found no substantial increase in the likelihood of a positive test for Covid-19 or in the risk of severe Covid-19 among patients who tested positive in association with five common classes of antihypertensive medications (NEJM)
Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19
In this large, population-based study, the use of ACE inhibitors and ARBs was more frequent among patients with Covid-19 than among controls because of their higher prevalence of cardiovascular disease. However, there was no evidence that ACE inhibitors or ARBs affected the risk of COVID-19 (NEJM)
The impact of diabetes on COVID-19 infection
Not unexpectedly, diabetes has been identified as posing a particular adverse risk, along with chronic renal and coronary heart disease, and such surrogate risk indicators as obesity and hypertension (Practical Diabetes)
Glycosmedia is also available as an App: